Acadia falls as NDA timeline slows, CEO retires

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shed $13.26 (30%) to $31.50 in after-hours trading after it said it would delay to 2H15 its NDA submission for Nuplazid pimavanserin to treat Parkinson's disease psychosis (PDP). It had planned the submission for this quarter.

Acadia said it needed additional time to prepare its commercial manufacturing systems, and noted that the delay is not related to Nuplazid's clinical or safety profile, nor is it a result of any interaction with FDA. The agency has granted breakthrough designation to the small molecule serotonin (5-HT2A) receptor inverse agonist to treat PDP. ...